ChemicalBook > CAS DataBase List > STATINE

STATINE

Product Name
STATINE
CAS No.
49642-07-1
Chemical Name
STATINE
Synonyms
STATIN;STATINE;H-STA-OH;S)-Statine;LEU-STATINE;4S)-Statine;(S,S)-Statine;H-STA(3S,4S)-OH;(3S,4S)-STATINE;H-(3S,4S)-STA-OH
CBNumber
CB9272763
Molecular Formula
C8H17NO3
Formula Weight
175.23
MOL File
49642-07-1.mol
More
Less

STATINE Property

Melting point:
209 °C
alpha 
D15 -20° (c = 0.64 in water)
Boiling point:
306.53°C (rough estimate)
Density 
1.1233 (rough estimate)
refractive index 
1.4476 (estimate)
storage temp. 
2-8°C
solubility 
0.5 M HCl: 50 mg/mL, clear, very faintly yellow
pka
3.97±0.10(Predicted)
form 
Solid
color 
White to off-white
Merck 
13,8879
More
Less

Safety

Hazard Codes 
Xi
Risk Statements 
36/37/38
Safety Statements 
26-36
WGK Germany 
3
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

P321Specific treatment (see … on this label).

P332+P313IF SKIN irritation occurs: Get medical advice/attention.

P362Take off contaminated clothing and wash before reuse.

More
Less

N-Bromosuccinimide Price

American Custom Chemicals Corporation
Product number
API0004236
Product name
STATINE
Purity
95.00%
Packaging
50MG
Price
$340.2
Updated
2021/12/16
More
Less

STATINE Chemical Properties,Usage,Production

Chemical Properties

white powder

Mechanism of action

The statin family of six closely related hypocholesterolemic drugs are all potent competitive inhibitors of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA reductase), the rate-limiting enzyme in cholesterol biosynthesis.The liver is their target organ, and decreased hepatic cholesterol synthesis ultimately leads to increased removal of LDL particles from the circulation. As a consequence, all other hypocholesterolemic drugs have been relegated to secondary status.
Clinical trials with lovastatin (Mevacor), simvastatin (Zocor) and pravastatin (Pravachol) provided much of the evidence supporting the observation that lowering of blood cholesterol lowers the risk of CHD. Reductions in CHD risk appear to be due to multiple consequences of inhibiting the cholesterol synthesis pathway. Drug-induced inhibition of hepatic cholesterol synthesis leads to lowering of liver cholesterol concentrations and feedback up-regulation at the gene level of both HMG CoA reductase and the LDL receptor (mechanisms IV and VII in Fig. 23.2). As long as the statin is present at adequate concentration in the liver, the extra HMG CoA reductase activity is not expressed. However, the increased hepatic LDL receptor protein results in increased rates of removal of LDL particles from the circulation by the liver, lowering of blood LDL-cholesterol levels, slowing of atherosclerosis, and decreased risk of heart attack.
The reduced risk of CHD achieved with the statins may also be due to drug actions independent of lowering blood cholesterol. Many important molecules besides cholesterol are generated by intermediates in the complex cholesterol synthesis pathway. These include the isoprenes geranylgeranyl and farnesyl, which are covalently attached to some proteins (isoprenylation) and target them to membranes where they function.The re-ported capacities of statins to inhibit proliferation of arterial wall smooth muscle cells and to improve endothelial cell functions may be due to inhibited protein isoprenylation in these cells secondary to HMG CoA reductase inhibition.

Clinical Use

With the possible exception of atorvastatin, the statins are used to lower LDL cholesterol in familial or polygenic ( multifactorial) hypercholesterolemia (type IIa) and in combination with triglyceride-lowering drugs to treat combined hyperlipidemia (type IIb) when both LDL and VLDL (very low density lipoproteins) are elevated. However, the statins probably should not be given with the fibrates (triglyceridelowering drugs, discussed later), since this combination may greatly increase statin toxicity. Atorvastatin, the most potent of the available statins, has also been shown to lower blood triglycerides significantly.
This effect may be due to decreasing hepatic cholesterol and cholesterol ester levels to such an extent that hepatic formation of VLDL is impaired.The statins also have been claimed to reduce blood cholesterol levels modestly in some patients with homozygous familial hypercholesterolemia, a condition often fatal in childhood or in early adulthood.
The statins may lower the risk of CHD by decreasing inflammation, an important component of atherogenesis. Lovastatin decreased elevated plasma levels of Creactive protein, a marker for cellular inflammation, and acute coronary events in patients with relatively low plasma cholesterol levels. Recent studies also suggest that use of statins may decrease the risk of stroke, dementia, and Alzheimer’s disease and may improve bone density in postmenopausal women. These broad actions may be related to the hypocholesterolemic, antiproliferative, antiinflammatory, or antioxidant properties of the statins or some combination of these properties.

Side effects

The statins generally appear to be well tolerated, with muscle pain and liver dysfunction seen in 1 to 2% of patients. However, the consequences of 20 to 30 years of continuous use are unknown. This fact has been dramatically reinforced by the recent recognition of a potentially fatal consequence of statin use. A relatively common side effect of the statins (perhaps 1% of patients) is myositis, that is, inflammation of skeletal muscle accompanied by pain, weakness, and high levels of serum creatine kinase. Rhabdomyolysis, i.e., disintegration of muscle with urinary excretion of myoglobin and kidney damage, was considered to be a rare and extreme toxic outcome. However, cerivastatin (Baycol) has now been withdrawn from the market by its manufacturer (Bayer) because of 31 deaths linked to fatal rhabdomyolysis. The risk of muscle damage is said to increase with simultaneous use of the triglyceride-lowering fibrates. Pravastatin may be less toxic than other statins because it does not readily penetrate extrahepatic cells and may be more confined to the liver after oral dosage.

STATINE Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

STATINE Suppliers

Beijing Ouhe Technology Co., Ltd
Tel
010-82967028 13552068683
Fax
+86-10-82967029
Email
2355560935@qq.com
Country
China
ProdList
12438
Advantage
60
Shanghai Hanhong Scientific Co.,Ltd.
Tel
021-54306202 13764082696
Email
info@hanhongsci.com
Country
China
ProdList
42958
Advantage
64
Chemsky (shanghai) International Co.,Ltd
Tel
021-50135380
Email
shchemsky@sina.com
Country
China
ProdList
15402
Advantage
60
SHANGHAI FORTUNE CHEMICAL TECHNOLOGY CO., LTD
Tel
13816107857
Fax
qq: 276312098
Email
sales@fortunechem-sh.com
Country
China
ProdList
289
Advantage
58
MedChemexpress LLC
Tel
021-58955995
Fax
609-228-5909
Email
sales@medchemexpress.cn
Country
United States
ProdList
4861
Advantage
58
Aikon International Limited
Tel
025-66113011 18112977050
Fax
(5)02557626880
Email
cb6@aikonchem.com
Country
China
ProdList
15494
Advantage
58
Hangzhou Peptidego Biotech Co.,Ltd.
Tel
0571-87213919
Fax
0571-87213919
Email
Eric@peptidego.com
Country
China
ProdList
6756
Advantage
58
BOC Sciences
Tel
16314854226; +16314854226
Email
inquiry@bocsci.com
Country
United States
ProdList
19741
Advantage
58
TargetMol Chemicals Inc.
Tel
+1-781-999-5354 +1-00000000000
Email
marketing@targetmol.com
Country
United States
ProdList
32063
Advantage
58
Nextpeptide Inc
Tel
+86-0571-81612335 +8613336028439
Email
sales@nextpeptide.com
Country
China
ProdList
19908
Advantage
58

49642-07-1, STATINERelated Search:


  • STATIN
  • STATINE
  • H-STA(3S,4S)-OH
  • H-STA-OH
  • H-(3S,4S)-STA-OH
  • LEU-STATINE
  • (3S,4S)-4-AMINO-3-HYDRO-6-METHYLHEPTANOIC ACID
  • (3S,4S)-(-)-STATINE
  • (3S,4S)-STATINE
  • (3S,4S)-4-AMINO-3-HYDROXY-6-METHYLHEPTANOIC ACID
  • (3S,4S)-4-AMINO-3-HYDROXY-L-METHYLHEPTANOIC ACID
  • Sta(3S,4S)-OH·HCl
  • Statine Hydrochloride≥ 98% (TLC)
  • Statine *CAS 49642-07-1*
  • (3S,4S)-(-)-Statine,98%
  • (3S,4S)-4-Amino-3-hydroxy-6-methylheptanoic acid hydrochloride
  • (S,S)-Statine
  • Heptanoic acid, 4-amino-3-hydroxy-6-methyl-, (3S,4S)-
  • 4S)-Statine
  • S)-Statine
  • 49642-07-1
  • Unnatural Amino Acid Derivatives
  • Peptide Synthesis
  • Others
  • Specialty Synthesis
  • Amino Acids